Uso de nanopartículas en el tratamiento del lupus eritematoso sistémico

  1. Paula Cilleros Holgado 1
  2. Rubén Jurado Escobar 1
  1. 1 Universidad Pablo de Olavide
    info

    Universidad Pablo de Olavide

    Sevilla, España

    ROR https://ror.org/02z749649

Revista:
MoleQla: revista de Ciencias de la Universidad Pablo de Olavide

ISSN: 2173-0903

Año de publicación: 2020

Número: 39

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: MoleQla: revista de Ciencias de la Universidad Pablo de Olavide

Resumen

—El lupus eritematoso sistémico es una enfermedad autoinmune crónica sistémica que afecta a todos los órganos y sistemas del cuerpo humano. Existen diversas estrategias farmacológicas para su tratamiento, la mayoría de ellas basadas en la reducción de la inflamación característica de la patología. Sin embargo, presentan múltiples efectos secundarios y solo reducen levemente la sintomatología, por lo que la aplicación de nanopartículas mejoraría la eficacia terapéutica y conseguiría reducir dichos efectos adversos.

Referencias bibliográficas

  • C. Mok, C. Lau. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol., 56 (7) (2003), pp. 481-490
  • W. Xiong, R.G. Lahita. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat. Rev. Rheumatol., 10 (2) (2014), pp. 97-107
  • G.C. Tsokos, G.M. Kammer. Molecular aberrations in human systemic lupus erythematosus. Mol. Med. Today, 6 (11) (2000), pp. 418-424
  • J. Tyrrell‐Price, P.M. Lydyard, D.A. Isenberg. The effect of interleukin‐10 and of interleukin‐12 on the in vitro production of anti‐double‐stranded DNA antibodies from patients with systemic lupus erythematosus. Clin. Exp. Immunol., 124 (1) (2001), pp. 118-125
  • S.A. Apostolidis, L.A. Lieberman, K. Kis-Toth, J.C. Crispín, G.C. Tsokos. The dysregulation of cytokine networks in systemic lupus erythematosus. J. Interferon Cytokine Res., 31 (10) (2011), pp. 769-779
  • B. Hahn. The Pathogenesis of SLE, Dubois’ Lupus Erythematosus and Related Syndromes. (8th ed.), Elsevier Saunders, Philadelphia (2013), pp. 25-34
  • L. Ronnblom, G.V. Alm, M.-L. Eloranta. The type I interferon system in the development of lupus. Seminars in Immunology, Elsevier (2011), pp. 113-121
  • JD. Yu, C.G. Vinuesa. The elusive identity of T follicular helper cells. Trends Immunol., 31 (10) (2010), pp. 377-383.
  • N. Simpson, P.A. Gatenby, A. Wilson, S. Malik, D.A. Fulcher, S.G. Tangye, H. Manku, T.J. Vyse, G. Roncador, G.A. Huttley. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheumatism, 62 (1) (2010), pp. 234-244.
  • S.Y. Bang, J.Y. Choi, S. Park, J. Choi, S.J. Hong, H.S. Lee, C.B. Choi, S.C. Bae. Brief report: influence of HLA?DRB1 susceptibility alleles on the clinical subphenotypes of systemic lupus erythematosus in Koreans. Arthritis Rheumatol., 68 (5) (2016), pp. 1190-1196
  • M. Barbhaiya, K.H. Costenbader. Environmental exposures and the development of systemic lupus erythematosus. Curr. Opin. Rheumatol. (2016).
  • A. Bengtsson, L. Rönnblom. Systemic lupus erythematosus: still a challenge for physicians. J. Intern. Med. (2016)
  • B. Dema, N. Charles. Advances in mechanisms of systemic lupus erythematosus. Discov. Med., 17 (95) (2014), pp. 247-255.
  • W. Huang, J. Sinha, J. Newman, B. Reddy, L. Budhai, R. Furie, A. Vaishnaw, A. Davidson. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheumatism, 46 (6) (2002), pp. 1554-1562.
  • A.Y. Hoi, G.O. Littlejohn. Abatacept in the treatment of lupus. Expert Opin. Biol. Ther., 12 (10) (2012), pp. 1399-1406.
  • S. Dolati, S. Sadreddini, D. Rostamzadeh, M. Ahmadi, F. Jadidi-Niaragh, M. Yousefi. Utilization of nanoparticle technology in rheumatoid arthritis treatment. Biomed. Pharmacother., 80 (2016), pp. 30-41.
  • R. Stevenson, A.J. Hueber, A. Hutton, I.B. McInnes, D. Graham. Nanoparticles and inflammation. Sci. World J., 11 (2011), pp. 1300-1312.
  • M. Hosseini, M. Haji-Fatahaliha, F. Jadidi-Niaragh, J. Majidi, M. Yousefi. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artificial Cells Nanomed. Biotechnol., 44 (4) (2016), pp. 1051-1061.
  • O.C. Farokhzad, R. Langer. Impact of nanotechnology on drug delivery. ACS Nano, 3 (1) (2009), pp. 16-20.
  • J. Shi, A.R. Votruba, O.C. Farokhzad, R. Langer. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano
  • X. Clemente-Casares, P. Santamaria. Nanomedicine in autoimmunity. Immunol. Lett., 158 (1) (2014), pp. 167-174.
  • D.M. Smith, J.K. Simon, J.R. Baker Jr.. Applications of nanotechnology for immunology. Nat. Rev. Immunol., 13 (8) (2013), pp. 592-605.
  • D.A. Fox. Biological therapies: a novel approach to the treatment of autoimmune disease. Am. J. Med., 99 (1) (1995), pp. 82-88.
  • F. Yuan, G.M. Thiele, D. Wang. Nanomedicine development for autoimmune diseases. Drug Dev. Res., 72 (8) (2011), pp. 703-716.
  • M.M. Schwartz. The pathology of lupus nephritis. Seminars in Nephrology, Elsevier (2007), pp. 22-34.
  • T.S. Zimmermann, A.C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M.N. Fedoruk, J. Harborth, J.A. Heyes, L.B. Jeffs, M. John. RNAi-mediated gene silencing in non-human primates. Nature, 441 (7089) (2006), pp. 111- 114.
  • Y. Tang, X. Luo, H. Cui, X. Ni, M. Yuan, Y. Guo, X. Huang, H. Zhou, N. de Vries, P.P. Tak. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheumatism, 60 (4) (2009), pp. 1065-1075.
  • H. Shimizu, Y. Hori, S. Kaname, K. Yamada, N. Nishiyama, S. Matsumoto, K. Miyata, M. Oba, A. Yamada, K. Kataoka. siRNA-based therapy ameliorates glomerulonephritis. J. Am. Soc. Nephrol., 21 (4) (2010), pp. 622-633.
  • M. Look, W.M. Saltzman, J. Craft, T.M. Fahmy. The nanomaterialdependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials, 35 (3) (2014), pp. 1089-1095.
  • M.W. Look, E. Stern, Q. Wang, L. DiPlacido, J.E. Craft, T.M. Fahmy. Lupus immunotherapy using CD4 targeted nanoparticles. J. Immunol., 182 (Meeting Abstracts 1) (2009) (48.29).
  • M. Look, E. Stern, Q.A. Wang, L.D. DiPlacido, M. Kashgarian, J. Craft, T.M. Fahmy. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J. Clin. Invest., 123 (4) (2013), p. 1741.
  • S. Sakaguchi, M. Ono, R. Setoguchi, H. Yagi, S. Hori, Z. Fehervari, J. Shimizu, T. Takahashi, T. Nomura. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease. Immunol. Rev., 212 (1) (2006), pp. 8-27.
  • S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono. Regulatory T cells and immune tolerance. Cell, 133 (5) (2008), pp. 775-787.
  • J. Park, W. Gao, R. Whiston, T.B. Strom, S. Metcalfe, T.M. Fahmy. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol. Pharm., 8 (1) (2010), pp. 143-152.
  • K.M. Hasebroock, N.J. Serkova, S.A. Sargsyan, B. Renner, B. Larsen, C. Stoldt, V.M. Holers, J.M. Thurman. Non-invasive assessment of disease activity in a model of lupus nephritis using complement receptor-2 conjugated to superparamagnetic iron oxide nanoparticles. Mol. Immunol., 47 (13) (2010), p. 2292
Fuente de los datos: Dialnet